Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry.
CVS Health Corp on Wednesday forecast 2019 profit well below Wall Street estimates due to weakness in its pharmacy business that serves long-term care facilities and slower than anticipated growth in drug prices, sending shares down 8 percent.
Intercept Pharmaceuticals Inc said on Tuesday its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ, taking the drug a step closer to approval and sending the company's shares surging 25 percent.
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.
Johnson & Johnson said on Wednesday it would buy Auris Health Inc for $3.4 billion in cash, gaining access to the privately held company's surgical robotic scope used in respiratory procedures and the detection of lung cancer.
Gene therapy company UniQure NV said on Friday its treatment for hemophilia B increased the levels of a protein that helps in blood clotting after 12 weeks in a relatively small study.
Humana Inc's full-year profit forecast came in shy of analysts' estimates on Wednesday as its Medicare Prescription drug plans remained under pressure and said it expects 2019 margins in the fast-growing business to fall short of its own targets.
(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7)